carbon dioxide inhalation; periodic breathing IDIOPATHIC CENTRAL SLEEP APNEA SYNDROME (ICSAS) is an uncommon disorder characterized by recurrent central apneas during sleep in the absence of ventilatory failure, cardiac failure, or neuromuscular diseases and in association with symptoms of central sleep apnea (7) . Central apneas in patients with ICSAS are precipitated by abrupt increases in tidal volume (VT) and minute ventilation (V I), often in association with arousals from sleep, which are accompanied by reductions in PCO 2 (30) . These observations indicate that central apneas in ICSAS are posthyperventilatory in nature. In addition, our laboratory has previously demonstrated that compared with healthy control subjects, those with ICSAS chronically hyperventilate in association with hypocapnia both while they are asleep and while awake (29) . Furthermore, both central and peripheral chemoresponsiveness in patients with ICSAS are increased compared with healthy control subjects, suggesting that increased ventilatory responsiveness to chemical respiratory stimuli may play a role in provoking hyperventilation and hypocapnia (29, 30) . Taken together, these data led us to propose that chronic and acute hyperventilation interact in such a way as to precipitate central apneas during sleep: the former may maintain arterial PCO 2 (Pa CO 2 ) close to the apnea threshold, and the latter may drive Pa CO 2 below this threshold, resulting in central apneas. Arousals may facilitate this process by causing abrupt increases in V I and reductions in Pa CO 2 .
If recurrent reductions in Pa CO 2 below the threshold for apnea are the mechanism responsible for central apneas during sleep in patients with ICSAS, we reasoned that raising and maintaining Pa CO 2 above the apneic threshold should abolish central apneas in these patients. To test this hypothesis, we examined the effects of raising Pa CO 2 on central apneas in patients with ICSAS. This was accomplished either by having them inspire a CO 2 -enriched gas mixture or by having them breathe through a face mask with added dead space during sleep to increase the fraction of inspired CO 2 (FI CO 2 ). To this end, patients with ICSAS were studied overnight under four different conditions: 1) room air breathing; 2) alternating room air and CO 2 inhalation, 3) CO 2 inhalation all night, and 4) breathing through a face mask with added dead space all night.
METHODS

Patients
Six patients with ICSAS (all men, aged 54-71 yr) were recruited for the study. ICSAS was defined as apneas and hypopneas occurring at a rate of $10 apneas and hypopneas/h of sleep, of which at least 75% had to be central in nature, without associated CO 2 retention (a daytime Pa CO 2 # 45 Torr), hypoxia (arterial PO 2 .70 Torr), lung disease, heart failure, neurological disease, or renal dysfunction in association with two or more the following symptoms: habitual snoring, nocturnal choking, restless sleep, insomnia, or excessive daytime sleepiness. Patients were not permitted to take any stimulants, including caffeinated beverages, for at least 24 h or sedatives for at least 48 h before experiments. Written informed consent was obtained from all the patients, and the experimental protocols were approved by the Human Subjects Review Committee of the University of Toronto.
Experimental Setup
Sleep and ventilatory monitoring. Routine overnight sleep studies were performed on each patient as previously described (30) . Sleep stages were identified by electroencephalogram (C3/A2; C4/A1), electroocculogram, and submental electromyogram recordings obtained from surface electrodes and were scored according to standard criteria (23) . Movement arousals were defined by standard criteria as an increase in submental electromyographic activity accompanied by an increase in alpha activity or by paroxysmal bursts of highvoltage electroencephalographic activity (23) . The electrocardiogram was monitored from a precordial lead. Thoracoabdom-inal motion was monitored by respiratory inductance plethysmography (Respitrace, Ambulatory Monitoring, White Plains, NY). VT was taken as the electrical sum of the rib cage and abdominal displacements, which was calibrated against a spirometer by the two positions-simultaneous equations method (8, 28) . Esophageal pressure was assessed by using a balloon-catheter system during the first night to accurately determine apnea type. Central apneas were defined by the absence of VT excursion for at least 10 s in the absence of esophageal pressure swings and thoracoabdominal movement. Central hypopneas were defined as a 50% or greater reduction in VT from the baseline value persisting for at least 10 s in the absence of phase shift or paradoxical motion of the rib cage and abdomen and in which esophageal pressure excursions paralleled reductions in VT (16, 29, 30) . Apneas and hypopneas that were associated with phase shift or outright paradoxical motion of the rib cage and abdomen and/or progressive increases in esophageal pressure excursions were defined as obstructive. Periodic breathing was defined as at least three consecutive cycles of hyperpnea alternating with central apnea or hypopnea (30) . Oxyhemoglobin saturation (Sa O 2 ) was continuously measured by an ear oximeter (Oxyshuttle, Sensormedics, Anaheim, CA). Transcutaneous PCO 2 (Ptc CO 2 ) was continuously measured with a transcutaneous monitor (Kontron Medical, HoffmanLaRoche, Basel, Switzerland) with the CO 2 electrode on the anterior chest wall. The instrument was calibrated as previously described in our laboratory (21) and was recalibrated at the end of the study to PCO 2 of 23 and 55 Torr. The PCO 2 during recalibration at the end of the overnight study was always within 2 Torr of the test-gas value. Expired air was sampled from nasal prongs inside the nares, from which the fraction of end-tidal CO 2 (FET CO 2 ) was measured by an infrared CO 2 analyzer (model LB-2, Beckman, Schiller Park, IL). The instrument was calibrated at the beginning of each study and recalibrated at the end of the study by using dry gas samples of 3, 5, and 8.4% CO 2 . The offset was within 0.1%. Data were recorded on a 16-channel polygraph (model 78D, Grass Instruments, Quincy, MA) at a speed of 1 cm/s. Ptc CO 2 and Sa O 2 were also recorded on a separate strip-chart recorder (type C7025A, Linseis, Princeton, NJ) at a speed of 1 cm/min. CO 2 delivery system. The FI CO 2 was controlled by mixing a CO 2 -enriched gas (3% CO 2 -21% O 2 -76% N 2 ) and compressed air in a Douglas bag with a capacity of 120 liters. The bag was maintained partially full during the period of CO 2 inhalation by supplying it with the gas mixture at a flow rate of ,10-15 l/min, which was varied according to each patient's V I. The FI CO 2 was adjusted between 1 and 2.3% by manually controlling the flow rates of the two gas streams. The patients breathed through a tight-fitting face mask, with separate inspiratory and expiratory valves (Downs CPAP Mask, Vital Signs). The Douglas bag was connected to a three-way stopcock, which was, in turn, connected to the inspiratory port of the face mask by vinyl tubing 2 m in length and 17 mm in internal diameter. Therefore, the circuit allowed the subjects to breathe either room air or the CO 2 -enriched gas mixture from the Douglas bag by turning the three-way stopcock. Patients expired through the expiratory port of the face mask, which minimized dead space. The concentration of CO 2 in the Douglas bag and the switching of the inspired gas between room air and the CO 2 mixture were controlled by the experimenter in a separate room from the patient to minimize sleep disruption.
Dead-space system. The dead-space system consisted of a face mask with a single opening onto which were fitted various lengths of wide-bore tubing (65-mm ID) fitted to the port of the face mask (20-mm ID) to increase the FI CO 2 by the rebreathing of expired gas. At the maximum volume used (700 ml), the dead-space apparatus had a negligible resistance (0.1 cmH 2 O·l 21 · s at 3 Hz and 0.2 cmH 2 O·l 21 · s at 7 Hz) measured by an airway hypersensitivity monitor (Astograph model TCK-6000M, Chest, Tokyo, Japan).
Protocol
The studies were conducted on four consecutive nights in the sleep laboratory. The first night (N1) served as a control night, during which patients breathed room air and no face mask was worn. During the second night (N2), patients went to sleep wearing a face mask, initially breathing room air. Once stage 2 (S2) non-rapid-eye-movement (NREM) sleep with recurrent central apneas became established for 5 min, the CO 2 -enriched gas mixture was administered for 1 h, after which room air and the CO 2 mixture were alternated at 1-h intervals for the rest of the night. The initial FI CO 2 was 1% and was then gradually increased if apneas persisted. Because during the N2 study we found that an FI CO 2 of 1.0-2.0% was sufficient to abolish central apneas in all patients, on the third night (N3), the patients were administered an FI CO 2 slightly higher than during N2 (1.5-2.3%) to ensure that Ptc CO 2 was increased at least as much as it was on N2. Four of the six patients agreed to undergo a 4th study night during which they breathed through a face mask with added dead space (N4). After room air breathing for 1 h, the face mask was applied and dead space was added in increments of 100 ml.
Data Analysis
Sleep stages and respiratory events were scored by a single technician. Stable breathing was defined as periods of rhythmic breathing lasting at least 3 min during which there were no apneas or hypopneas. The number of apneas per hour of sleep was defined as the apnea index (AI) and the number of apneas and hypopneas per hour of sleep as the apneahypopnea index (AHI). FET CO2 was taken from the end of the expiratory plateau (11) . Baseline FET CO 2 and VT were determined by averaging the FET CO2 and VT of breaths during stable room air breathing in S2 sleep for 15 min. A 15-min period was chosen because this was the maximum amount of stable breathing in some of the patients. Preapneic FET CO 2 was determined by averaging the FET CO 2 of the last three breaths of the hyperpnea preceding every central apnea in S2 sleep for the N2 study. The mean preapneic FET CO 2 was calculated and the maximum preapneic FET CO 2 was measured for each subject during S2 sleep of the N2 study. The coefficients of variation of FET CO 2 , VT and total respiratory cycle length (Ttot) were calculated. For N2, the analysis of breathing parameters was restricted to S2 sleep to control for effects of sleep state on breathing and because central apneas occur predominantly in this sleep stage in patients with ICSA (29, 30) . For N1 and N3 studies, however, all sleep and respiratory data were scored and compared. For N4, the effect of adding dead space was analyzed by comparing the respiratory parameters with and without addition of dead space during S2 sleep. Comparisons were made by paired t-tests between conditions of CO 2 inhalation and room air breathing both for N2 and for N1 vs. N3. Because of the low sample size and high variance of baseline parameters among the four patients participating in the dead-space protocol, comparisons between dead-space and room air breathing on N4 were by analysis of variance controlling for differences in baseline values. In addition, during N2, the FET CO 2 for preapneic breaths, during stable breathing during room air breathing and during stable breathing during CO 2 inhalation were compared by analysis of variance for repeated measures with post hoc analysis by Newman-Keuls test to determine where significant differences lay. A P value of , 0.05 was considered to be statistically significant. Data are expressed as means 6 SE. Table 1 shows the characteristics of patients and their respiratory data from the N1 study. All six patients were men who were slightly overweight. They were normoxic and mildly hypocapnic while awake and had frequent apneas and hypopneas associated with mild O 2 desaturation and a low mean Ptc CO 2 while asleep, as our laboratory has previously described (29, 30) . Moreover, apneas and hypopneas occurred predominantly in S2 sleep (80.2% of total apneas and hypopneas) in association with periodic breathing.
RESULTS
Characteristics of Patients
CO 2 Inhalation Vs. Room Air Breathing During N2
All patients had episodes of stable breathing and periodic breathing while breathing room air. As shown in Fig. 1 , compared with stable breathing during room air breathing, the ventilatory pattern during periodic breathing was characterized by higher VT and consequently lower FET CO2 just before the onset of apnea. In fact, reductions in FET CO 2 invariably preceded central apneas during S2 sleep. The maximum preapneic FET CO 2 in the patients, which should be close to the apneic threshold, was on average 0.29% (2 Torr) lower than baseline FET CO 2 during stable breathing in S2 sleep. FET CO 2 during stable breathing during room air breathing did not fall lower than this without precipitating a central apnea. In addition, inhalation of the CO 2 -enriched gas caused an increase in FET CO 2 and reduced its variability compared with stable breathing during room air breathing. Similarly, the group data in Fig. 2 show that the preapneic FET CO 2 was significantly lower than during stable breathing during room air breathing and that FET CO 2 during CO 2 inhalation was higher than during both stable breathing and preapneic breaths. Moreover, group data in Fig. 3 show that CO 2 inhalation reduced the coefficients of variation of VT and FET CO 2 but not of Ttot. The stabilizing effect of CO 2 inhalation on breathing was further evidenced by abolition of periodic breathing and dips in Sa O 2 (Fig. 4) . Individual data for S2 sleep during the N2 study are presented in Table 2 . Central apneas and hypopneas were virtually abolished by CO 2 inhalation. The few isolated central apneas that were observed during CO 2 inhalation in patients 2 and 5 occurred as FET CO 2 was being titrated upward and when FET CO 2 decreased below the room air preapneic level. At higher FET CO 2 values, this did not occur. Because of the reduction in central events, the proportion of time spent in stable breathing during S2 sleep was significantly longer during CO 2 inhalation than during room air breathing. The improvement of breathing during CO 2 inhalation was associated with significant increases in mean Ptc CO 2 Table 3 illustrates that at baseline, sleep was fragmented by frequent movement arousals with reductions in the amounts of slow-wave and rapid-eyemovement (REM) sleep, as one would expect in a sleep apnea disorder (29, 30) . However, neither sleep stage distribution nor frequency of movement arousals changed from N1 to N3, but inhalation of CO 2 during N3 caused significant increases during sleep in mean Ptc CO 2 and mean Sa O 2 of 2.4 Torr and 2.1%, respectively. Furthermore, Table 4 and Fig. 5 demonstrate a reduction in AI and AHI in every patient for all sleep stages except REM sleep. These reductions in AI and AHI were due entirely to significant reductions in central apneas and hypopneas but not to obstructive apneas or hypopneas, which occurred predominantly in REM sleep (Fig. 6 ).
Dead-Space Night (N4)
Patients spent an average of 0.88 6 0.40 h of S2 sleep without dead space and 2.44 6 0.65 h breathing through added dead space. Figure 7 shows a polysomnographic recording from the same patient as shown in Fig. 1 during S2 sleep. It demonstrates that addition of 500 ml of dead space caused an increase in FET CO 2 and stabilization of breathing similar to that induced by CO 2 inhalation. As shown in Fig. 8 , addition of 400-700 ml of dead space to the face mask caused a significant increase in Ptc CO 2 during S2 sleep, averaging 1.4 Torr, but no significant increase in mean Sa O 2 . The increase in Ptc CO 2 was accompanied by significant reductions in AI and AHI similar to those seen during CO 2 inhalation.
DISCUSSION
The present study provides important insights into the pathophysiology of central apneas during sleep in patients with ICSAS. First, we found that just before the onset of central apneas, FET CO 2 fell below the baseline level during stable breathing. This observation indicates that central apneas in ICSAS are critically dependent on reductions in Pa CO 2 below the apneic threshold because of hyperventilation. Second, confirmation of this mechanism was provided by the observation that raising Pa CO 2 above the apneic threshold, either by administering a CO 2 -enriched gas mixture or by adding dead space to a face mask, virtually abolished central apneas and hypopneas in these patients. Fig. 2 . Group data for FET CO 2 during stable breathing (SB) and preapneic breathing while inhaling room air and during SB while inhaling CO 2 on N2 during stage 2 sleep. Preapneic FET CO 2 (4.6 6 0.2%) was significantly lower than FET CO 2 during stable breathing during inhalation of room air (5.3 6 0.2%) or CO 2 (5.8 6 0.1%). FET CO 2 was higher during stable breathing during CO 2 breathing than during room air breathing. *** P , 0.005 compared with stable breathing during room air and CO 2 breathing. * P , 0.05 compared with stable breathing during room air breathing. Fig. 3 . Comparison of coefficients of variation of VT, total respiratory cycle time (Ttot), and FET CO 2 between conditions of stable breathing during room air breathing (solid bars) and during CO 2 inhalation (open bars) during stage 2 sleep of N2 study. CO 2 inhalation significantly reduced coefficients of variation of VT (from 34.4 6 6.6 to 13.8 6 3.8%) and FET CO 2 (from 4.7 6 0.9 to 2.4 6 0.3%) but not of Ttot (from 11.2 6 1.3 to 9.2 6 1.4%). * P , 0.025 compared with stable breathing during room air breathing.
Preapneic FET CO 2
Our laboratory previously demonstrated that central sleep apneas in patients with ICSAS were triggered by abrupt increases in ventilation (30) and that patients with ICSAS had significantly lower Pa CO 2 during sleep than did normal control subjects (29) . These observations strongly suggested that the Pa CO 2 of patients with ICSAS during NREM sleep was close to their apneic threshold, such that abrupt increases in V I were sufficient to drive Pa CO 2 below the apneic threshold. However, in these previous studies, breath-by-breath FET CO 2 was not measured, and, therefore, it was not possible to determine how far Pa CO 2 fell before the onset of central apneas. In the present study we have clearly demonstrated that FET CO 2 abruptly decreased below the baseline level just before the onset of central apneas. This decrease in FET CO 2 averaged 0.70% (,5 Torr), but the maximum FET CO 2 preceding central apneas was only 0.29% (,2 Torr) below the baseline level during stable breathing. These data indicate that the reduction in Pa CO 2 required to trigger a central apnea was ,2-3 Torr, which is less than the 3-to 6-Torr reduction below baseline reported to precipitate central apnea in normal subjects during NREM sleep (9, 25) . Our findings suggest that Pa CO 2 in patients with ICSAS is probably closer to the apneic threshold than it is in normal subjects without ICSAS. In addition, because apneas followed within a few seconds of the reduction in FET CO 2 during the last three breaths of hyperpneas, it is likely that inhibition of the peripheral chemoreceptors played a critical role in the initiation of central apneas because the time course would have been too short for inhibition of the central chemoreceptors. On the other hand, the central chemoreceptors probably played a role in determining the set point for a CO 2 response and the threshold for apnea (5, 9, 25) .
If periodic reductions in Pa CO 2 were responsible for triggering central apneas in patients with ICSAS, raising Pa CO 2 above apneic threshold should eliminate central apneas. Our data confirmed this hypothesis. Although CO 2 has been administered to alleviate central apneas associated with neurological or cardiac diseases (10, 18, 26) , after tracheostomy for obstructive sleep apnea (1), and for hypoxia-induced or hyperventilation-induced central apneas in experimental situations (5, 25) , in these studies, CO 2 was administered for Fig. 4 
Effects of Alternating Room Air and CO 2 Inhalation (N2)
Compared with room air breathing, CO 2 inhalation resulted in virtual abolition of central apneas and hypopneas. This improvement was associated with an increase in Ptc CO 2 of only 1.3 Torr and Sa O 2 by 2.1% during S2 sleep. The concurrent increase in FET CO 2 during CO 2 inhalation above that observed during preapneic and stable breathing during room air breathing (Fig. 2) confirmed that CO 2 inhalation increased Pa CO 2 . The stabilization of breathing by a small increase in Pa CO 2 is in agreement with Berssenbrugge and colleagues' observation (5) that increasing the FI CO 2 just enough to augment Pa CO 2 1-2 Torr could immediately abolish hypoxia-induced central apneas. Therefore, it is reasonable to attribute the abolition of central apneas and hypopneas during CO 2 inhalation to an increase in Pa CO 2 .
Another important effect of CO 2 inhalation observed during the N 2 study was the diminution of the breathto-breath variability of VT and FET CO 2 (Figs. 1 and 3 ). This finding is in accord with the previous observation that CO 2 inhalation consistently lowers the breathto-breath amplitudes of the oscillations in arterial pH (2) . During breathing of room air, Pa CO 2 fluctuates from breath to breath in association with fluctuations in VT (3, 27) . However, during the breathing of CO 2 , Pa CO 2 is more stable and its breath-to-breath oscillations are less affected by VT because alveolar PCO 2 is not diluted by inhalation of the CO 2 -enriched gas as much as it would be by inhalation of room air. The reductions in the breath-to-breath oscillations of Pa CO 2 and pH stabilize the signals detected by the peripheral chemoreceptors, which leads to stabilization of breathing (20) . Because peripheral chemoreceptors respond to breathto-breath fluctuations of Pa CO 2 and pH (4, 6, 12) , reduced breath-to-breath fluctuations in Pa CO 2 would stabilize their activity. This effect would be particularly important in patients with ICSAS because they have an increased peripheral ventilatory responsiveness to CO 2 compared with healthy control subjects, which tends to destabilize their breathing (29) . 
Effects of Overnight CO 2 Inhalation (N3)
The N3 study allowed us to assess the influence of inhaled CO 2 on sleep structure, to analyze the sustained effects of inhaled CO 2 on respiration in all sleep stages, and to distinguish the effects of CO 2 inhalation on central and obstructive respiratory events. First, we did not find significant differences in sleep-state distribution, frequency of movement arousals, or body position between N1 and N3 (Table 3) . Therefore, any change in respiration between N1 and N3 could not be attributed to differences in sleep states, the frequency of arousals, or body position. Although we have previously shown that arousals can precipitate central apneas by increasing V I and lowering PCO 2 (30) , during CO 2 inhalation, FET CO 2 did not decrease and, therefore, arousals did not trigger central apneas or hypopneas. Second, we confirmed the finding of the N2 study that raising Pa CO 2 by CO 2 inhalation virtually abolished central apneas and hypopneas. However, we extended these findings by showing that the effect of CO 2 inhalation was evident over an entire night and in all sleep stages except REM, where most of the events were obstructive. Third, during the N3 study, we were able to show that in contrast to central events, CO 2 inhalation had no significant effect on the frequency of obstructive apneas or hypopneas, most of which occurred during REM sleep. This finding indicates that CO 2 inhalation did not stabilize periodic breathing in our patients with ICSA primarily by reducing pharyngeal collapsibility (15, 18, 24) . Rather, it strengthens the assumption that Fig. 7 . Polysomnographic recordings from same patient as in Fig. 1 during dead-space night (N4) study. A: off dead space. B: on dead space. Patient had periodic breathing with central apneas throughout baseline period while breathing room air, as shown in A. Preapneic FET CO 2 was ,4.5%, similar to that shown in Fig. 1 . Later in the night when 500 ml of dead space were added, his FET CO 2 increased to 5.2% and his breathing became stable, as shown in B. 
Effects of Added Dead Space (N4)
We demonstrated that addition of 400-700 ml of dead space to the ICSAS patients increased FI CO 2 and Ptc CO 2 to the same degree as did inhalation of the CO 2 -enriched gas and, like the CO 2 -enriched gas, virtually eliminated central apneas and hypopneas. Thus it was shown that raising Pa CO 2 by two independent methods resulted in similar reductions in the frequencies of central apneas and hypopneas. These findings indicate that the most likely mechanism for abolition of central apneas by the addition of dead space was elevation of Pa CO 2 above the apnea threshold.
The dead-space protocol also provided additional information. During CO 2 inhalation because the fraction of inspired O 2 (FI O 2 ) was controlled at 21%, Sa O 2 increased probably through augmentation of V I due to CO 2 stimulation (Fig. 1) , by improvement of ventilationperfusion matching (19) , and by elimination of apneas and associated dips in Sa O 2 . However, during deadspace breathing, our patients exhibited no significant change in mean Sa O 2 . This lack of effect of dead space on Sa O 2 probably arose from the effects of increased V I and abolition of apneas, which prevented dips in Sa O 2 , vs. the countervailing effect of rebreathing expired air, which reduces FI O 2 . Therefore, the observations that the ICSAS patients in our study were normoxic awake and had only mild dips of Sa O 2 during apneas, in combination with the observation that dead space abolished central apneas without increasing mean Sa O 2 during sleep, argue against a primary role of hypoxia in the pathogenesis of ICSAS. Rather, they strengthen the case that elevation of Pa CO 2 was the primary mechanism underlying the inhaled CO 2 -induced and dead space-induced elimination of central sleep apneas. Further evidence for this was provided by previous work from our laboratory in which it was demonstrated that the initiation of periodic breathing was accompanied by increases in Sa O 2 in association with increases in ventilation and reductions in Pa CO 2 (30) . In addition, Badr et al. (1) showed that central apneas observed after a tracheostomy in a patient with obstructive sleep apnea were not affected by O 2 administration but were eliminated by CO 2 inhalation. Therefore, the increase in Sa O 2 during inhalation of the CO 2 -enriched gas was more likely the consequence rather than the cause of the abolition of central apneas. Nevertheless, we cannot rule out the possibility that apnea-related desaturation could secondarily facilitate further respiratory system instability in ICSA (20) .
Ideally, the four night studies should have been conducted in randomized order. However, for practical reasons, the order of the studies was not randomized. An overnight study during room air breathing was required before any intervention to provide baseline data and to confirm the diagnosis of ICSAS. Hence, the first night served as an acclimatization night and control night. Also, a CO 2 -titration study was required to determine the FI CO 2 required to eliminate central apneas for each patient before the overnight CO 2 inhalation study, and this was done on the second night. In addition, considering that two patients were not available for a fourth consecutive night, we gave priority to the CO 2 inhalation study, and, therefore, we used the third night as the all-night CO 2 inhalation study. Although the above four studies were not conducted in random order, this should have no impact on the validity of the outcomes because the effects of CO 2 inhalation and addition of dead space were similar on different nights and because during the portions of N2 and N4 when patients were breathing room air, apneas and hypopneas were similar in frequency to N1. The N1 study was performed without a face mask to obtain baseline data with minimal perturbation. However, it should be noted that the AHI during the room air portion of N2, when the patients were wearing a face mask, was identical to N1, suggesting that the face mask had no important effect on breathing pattern. Therefore, comparisons of N3 and N1 can reasonably be made. The two patients who did not agree to undergo the dead-space protocol (patients 3 and 6 in Tables 1  and 2 ) did so because of the inconvenience. However, this should not affect our results because they did not differ in any important way from the other four patients who completed the protocol.
FET CO 2 measurements reflect breath-to-breath alveolar CO 2 fraction but are dependent on the generation of sufficient ventilation to obtain an alveolar plateau. Therefore, this technique cannot measure alveolar CO 2 fraction during apneas or hypopneas. Accordingly, we used Ptc CO 2 monitoring as well, which continuously measures Ptc CO 2 in the presence or absence of ventilation and provides a measure of Pa CO 2 averaged over time. The two measurements of Ptc CO 2 and FET CO 2 behaved in parallel fashion in our patients. However, during room air breathing, the value of end-tidal PCO 2 derived from FET CO 2 tends to be lower than Pa CO 2 (13, 14) , whereas Ptc CO 2 tends to more accurately reflect Pa CO 2 (21) . In addition, during CO 2 inhalation, the increase in end-tidal PCO 2 is usually 2-3 Torr greater than the increase in Pa CO 2 (13, 14) . This explains why during the N2 study Ptc CO 2 increased by 1.3 Torr but FET CO 2 increased by 0.5% (,3.6 Torr). Thus the use of FET CO 2 provides important information about relative changes in Pa CO 2 but cannot necessarily be considered an accurate reflection of Pa CO 2 . Changes in Ptc CO 2 likely provided a more accurate reflection of Pa CO 2 .
In summary, we have demonstrated that an abrupt reduction in FET CO 2 immediately precedes the onset of the central apneas in patients with ICSAS. Furthermore, we have shown for the first time that inhalation of a CO 2 -enriched gas or addition of dead space eliminates central apneas and hypopneas in these patients in association with an increase in FET CO 2 and Ptc CO 2 and a dampening of breath-to-breath oscillations of FET CO 2 . These findings provide compelling evidence that the 925 EFFECT OF CO 2 ON CENTRAL SLEEP APNEA mechanism for initiation of central hypopneas and apneas in ICSAS is a reduction in Pa CO 2 toward or below the apneic threshold, respectively. Our data further indicate that the mechanism for abolition of these events by CO 2 inhalation and addition of dead space is by increasing and stabilizing Pa CO 2 above the apneic threshold. Taken together, these findings indicate that ICSAS is a disorder of respiratory control system instability that is Pa CO 2 dependent. Although the purpose of this study was not to test the clinical effects of increasing Pa CO 2 , our findings that CO 2 inhalation and addition of dead space eliminate central apneas and hypopneas point to their potential as treatments for this disorder. More studies over longer time periods will be required to test the therapeutic potential of these approaches.
